Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05088785 | Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer(FEStastic) | active not recruiting | N/A | 15 | Amsterdam UMC, location VUmcOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07608068 | Performance of Diffusion-weighted Imaging-based Virtual MR Elastography (vMRE) for Diagnosing Breast Cancer | active not recruiting | N/A | 238 | Yunnan Cancer HospitalOTHER | 1 | May 27, 2026 |
| clinicaltrials |
| NCT04588545 | Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease | active not recruiting | Phase 1 / Phase 2 | 33 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04648904 | Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer | active not recruiting | Early Phase 1 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06772181 | A Digital Health Intervention to Improve Symptoms and Physical Activity During Breast Radiation(PRO-ACTIVE) | active not recruiting | N/A | 40 | University of WashingtonOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT00585507 | Efficacy and Safety of 500mg of Fulvestrant | active not recruiting | Phase 2 | 40 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT00877500 | Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | active not recruiting | Phase 2 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT01251874 | Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer | active not recruiting | Phase 1 | 44 | National Cancer Institute (NCI)NIH | 1 | May 22, 2026 | clinicaltrials |
| NCT03125928 | Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | active not recruiting | Phase 2 | 16 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04522648 | Prospective Surveillance for Breast Cancer-Related Lymphedema(PROTECT) | active not recruiting | N/A | 250 | Rigshospitalet, DenmarkOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors(EXCEED) | active not recruiting | Phase 1 | 490 | Eli Lilly and CompanyINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT03870919 | Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients(PALATINE) | active not recruiting | N/A | 200 | UNICANCEROTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05006196 | Contrast-Free Magnetic Resonance Imaging for Breast Disease(IMOGEN) | active not recruiting | — | 1,030 | PerspectumINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT05675579 | A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) | active not recruiting | Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06760637 | Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease(FourLight-3) | active not recruiting | Phase 3 | 1,035 | PfizerINDUSTRY | 30 | May 19, 2026 | clinicaltrials |
| NCT03587740 | ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer | active not recruiting | Phase 2 | 111 | Dana-Farber Cancer InstituteOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04554927 | Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer(WEBAPPAC) | active not recruiting | N/A | 438 | Centre Francois BaclesseOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04769960 | Study of the Safety of MRI Scans in People Who Have Breast Tissue Expanders After Mastectomy | active not recruiting | — | 68 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT03983382 | A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients | active not recruiting | — | 190 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04622319 | A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) | active not recruiting | Phase 3 | 1,600 | Daiichi SankyoINDUSTRY | 31 | May 15, 2026 | clinicaltrials |
| NCT05374512 | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) | active not recruiting | Phase 3 | 644 | AstraZenecaINDUSTRY | 23 | May 15, 2026 | clinicaltrials |
| NCT05653752 | A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer | active not recruiting | Phase 1 | 80 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT05939128 | A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA(ERA) | active not recruiting | — | 625 | AstraZenecaINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT06043947 | Survival Monitoring in Russian Cancer Registries(SURVIMON) | active not recruiting | — | 100,000 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06618014 | Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)(NeoTOP) | active not recruiting | Phase 2 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT01937039 | Johns Hopkins Breast Cancer Program Longitudinal Repository | active not recruiting | — | 810 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05296746 | Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer(RIBOLARIS) | active not recruiting | Phase 2 | 1,100 | SOLTI Breast Cancer Research GroupOTHER | 3 | May 14, 2026 | clinicaltrials |
| NCT04314401 | National Cancer Institute "Cancer Moonshot Biobank" | active not recruiting | — | 1,600 | National Cancer Institute (NCI)NIH | 2 | May 13, 2026 | clinicaltrials |
| NCT05812924 | A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause | active not recruiting | Phase 2 | 18 | University of MiamiOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06663787 | Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment(HER2 CR) | active not recruiting | — | 50 | Nagoya City UniversityOTHER | 2 | May 13, 2026 | clinicaltrials |
| NCT07553702 | Dance Intervention in Breast Cancer Treatment | active not recruiting | N/A | 28 | Federal University of MaranhaoOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT01101425 | Male Breast Cancer: Understanding the Biology for Improved Patient Care | active not recruiting | — | 200 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 16 | May 12, 2026 | clinicaltrials |
| NCT02926911 | Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS(COMET) | active not recruiting | N/A | 997 | Alliance Foundation Trials, LLC.OTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03609047 | Adjuvant Palbociclib in Elderly Patients With Breast Cancer(Appalaches) | active not recruiting | Phase 2 | 366 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | May 12, 2026 | clinicaltrials |
| NCT03941730 | Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer | active not recruiting | Phase 2 | 8 | Mayo ClinicOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07475325 | Individual Factors Associated With Care Pathways Delays in Breast Cancer in Hauts-de-France.(E-C-HAU) | active not recruiting | — | 500 | University Hospital, LilleOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT01621659 | Multidisciplinary Team IntervenTion in CArdio-ONcology (TITAN Study)(TITAN) | active not recruiting | Phase 2 | 80 | University of AlbertaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04120298 | Effects of Exercise in Patients With Metastatic Breast Cancer(EFFECT) | active not recruiting | N/A | 357 | UMC UtrechtOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05319873 | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06387173 | Registry of Patients Undergoing Cryoablation for Early Stage Breast Cancer | active not recruiting | — | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06950008 | A Patient Navigation Intervention for the Improvement of Risk Management Among Women at High Risk of Breast Cancer | active not recruiting | N/A | 75 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05311397 | A Study of A166 in Patients With Advanced Solid Malignant Tumors | active not recruiting | Phase 1 | 120 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05347134 | SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | active not recruiting | Phase 3 | 254 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05464667 | Preoperative Irradiation for Stage I Breast Cancer | active not recruiting | N/A | 15 | Parul BarryOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05498896 | Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC(BARBICAN) | active not recruiting | Phase 2 | 146 | Queen Mary University of LondonOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06048718 | T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases(TUXEDO-4) | active not recruiting | Phase 2 | 28 | MedSIROTHER | 2 | May 8, 2026 | clinicaltrials |
| NCT06968585 | A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy(A166) | active not recruiting | Phase 3 | 365 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT04101851 | Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients With rCR and pCR in the Breast After NAST | active not recruiting | N/A | 350 | Toralf Reimer, MD PhDOTHER | 4 | May 7, 2026 | clinicaltrials |
| NCT04175210 | Prospective Randomized Study of Accelerated Radiation Therapy (PRART)(PRART) | active not recruiting | Phase 3 | 397 | Weill Medical College of Cornell UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 27, 2026source: clinicaltrials